

The Effect of Abdominal Massage in Managing Opioid-Induced Constipation

MASCC/ISOO

Annual Meeting on Suppportive Care in Cancer

www.mascc.org/meeting

Follow us on Twitter: @CancerCareMASCC

DİLEK YILDIRIM, GÜLBEYAZ CAN







Conflict of Interest Disclosure

Dilek YILDIRIM Dr., Gülbeyaz CAN Prof. Dr.

Has no real or apparent conflicts of interest to report.





Cancer Pain


 Pain is one of the most common symptoms, compromising QoL.






Pain Management

WHO's analgesic ladder



Opioid Effect on Bowel



CANCER CARE POSSIBLE

- Gastric motility
- Inhibits propulsion in the small and large intestines

Opioid-induced constipation



Opioid receptors, namely delta kappa and mü are widely throughout the GI tract.

Opioid receptor antagonists block opioid actions at peripheral opioid receptors that mediate decreased intestinal secretion and propulsive colonic motility.

Management opioid-induced constipation

Pharmacological

Non-Pharmacological

Opioid receptor antagonists

Fiber, fluid intake

Laxatives

Enemas

Abdominal massage

defecation physiology, normal defecation habits, defecation time and position

In the studies; Fluid consumption (1.5-2 liters /per day) is effective in the management of constipation, while some studies reported no effect.

In the studies; Although regular sports / exercise is effective in the management of constipation, some studies argue that it is not effective

In many studies conducted with the participation of different patient groups, abdominal massage administered 1-2 times a day for 3 to 7 days per week for 1 to 8 weeks has been reported to be an effective approach in the management of constipation associated with different causes.



21-23 JUNE SAN FRANCISCO

SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Study Purpose

Determine the effects of abdominal massage in managing opioid-induced constipation.





Study design & setting


Type : Randomized controlled trial

Timeline : February 2017 and January 2018

Setting : Pain Clinic at the Istanbul University
 Istanbul Medicine Faculty Hospital
 Istanbul, Turkey



Study design




2019
21-23 JUNE
SAN FRANCISCO
SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

The inclusion criteria for participation

- Be older than 18 years,
- ✓ Do not have any barriers (communicative, cognitive, affective, verbal, bowel problems, etc)
- ✓ Have been treated with opioids for at least 2 weeks
- ✓ Have had bowel excretion less than 3 times a week following the beginning of opioid treatment.
- Have had at least one of the opioid related congestion problems:
 - feeling of incomplete bowel emptying
 - ✓ gas /bloating
 - the feeling of defecation /pressure in anus



Sample Size





CANCER CARE POSSIBLE

Study Protocol

Visual Analog Scale

Last Interview **First Interview** Constipation Related Quality of Life Patient Information Form Constipation Related Quality of Life (PACQLQ) Control: Standard care Intervention: 15 min. abdominal massage 2 times a day for 4 week, 30 min. after breakfast and dinner Days 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 3**5** Daily bowel monitorization: Defecation Diary + Bristol Stool Scale + Visual Analog Scale **Daily bowel** monitorization: Defecation Diary + Bristol Stool Scale + 5 Follow-up interviews at the clinic or by the phone (15-20 min)



Abdominal massage application













Ethical considerations



the Istanbul University Istanbul Medicine Faculty Clinical Research Ethics Committee

Written and verbal consent for study attendance was obtained from each patient.



Data analysis



Univariate Analyses

- Chi-Square Test
- t test or Mann Whitney U test

Multiple regression analysis

backward method

Significance level was accepted as p < 0.05.



Demographic Characteristics

Sociodemographic characteristics		Intervention (Group (n=102)	Control Gr	oup (n=102)		
		$\overline{\mathbf{x}}$	± sd	X	± sd	t	р
Age		60.50	14.57	61.16	13.21	0.33	0.73
		n	%	n	%	χ²	р
	Female	35	34.3	45	44.1	2.05	0.15
Gender	Male	67	65.7	57	55.9		
Mantial Otatus	Single	21	20.6	17	16.7	0.51	0.47
Martial Status	Married	81	79.4	85	83.3		
	Primary School	50	49.0	48	47.1		
Education	Secondary school	17	16.7	13	12.7	6.15	0.29
Working Status	Employed	10	9.8	12	11.8	0.20	0.65
	Unemployed	92	90.2	90	88.2		



Clinical characteristics

Last day of	Intervention G	Group (n=102)	Control Gr	oup (n=102)	χ²	р
defecation	n	%	n	%		
Day 0 (Same day)	18	17.6	24	23.5		
1 day ago	29	28.4	22	21.6	4.70	.31
2 days ago	35	34.3	42	41.2	1.70	.01
3 days ago	9	8.8	9	8.8		
8-10 days ago	11	10.9	5	4.9		



Disease Related Characteristics

Medical Diagnosis	Experiment	al Group (n=102)	Control Group (n=102)		
Cancer	n	%	n	%	
Lung cancer	34	33.3	28	27.4	
Genitourinary System Cancers	13	12.7	14	13.7	
Breast Cancer	4	3.9	6	5.9	
Bone Cancer	5	4.9	1	0.9	
Hematological Cancers	3	2.9	7	6.9	
The sarcoma of soft tissue	6	5.9	1	0.9	
Head and Neck Cancers	2	1.9	4	3.9	
Brain Tumor	-	-	4	3.9	
Non-Cancer	35	34.3	37	36.2	



Daily opioid use

Opioids		Experimental	Control		
		_ x±Sd	x±Sd	Z _{MWU}	р
	1st week	143.7 ± 42.48	157.46 ± 43.81	-1.689	0.091
Codeine	2nd week	145.47 ± 41.14	156.36 ± 44.91	-1.167	0.243
(mg /day)	3rd week	145.42 ± 41.82	159.54 ± 42.81	-1.735	0.083
	4th week	146.34 ± 41.93	157.04 ± 42.77	-1.181	0.238
	5th week	145.07 ± 41.54	158.51 ± 43.00	-1.652	0.099
Tramadol	1st week	224.44 ± 110.05	214.78 ± 89.53	-0.223	0.823
(mg /day)	2nd week	228.19 ± 107.31	212.72 ± 89.8	-0.587	0.557
	3rd week	231.19 ± 113.12	216.16 ± 88.56	-0.478	0.633
	4th week	222.24 ± 110.07	225.64 ± 95.96	-0.359	0.720
	5th week	227.88 ± 111.68	218.48 ± 92.41	-0.237	0.813
Morphine	1st week	44.62 ± 25.63	47.89 ± 28.44	-0.908	0.364
(mg /day)	2nd week	44.25 ± 25.41	47.05 ± 28.56	-0.742	0.458
	3rd week	43.9 ± 25.19	46.38 ± 28.64	-0.728	0.466
	4th week	45.71 ± 27.51	49.25 ± 30.12	-0.933	0.351
	5th week	51.14 ± 32.72	46.59 ± 27.76	-0.068	0.946
Transdermal	1st week	24.56 ± 15.52	23.92 ± 13.13	-0.095	0.925
Fentanyl	2nd week	25.84 ± 15.85	23.88 ± 13.25	-0.288	0.773
(mcg /24 st)	3rd week	26.49 ± 15.91	24.63 ± 12.94	-0.211	0.833
	4th week	27.83 ± 16.61	25.28 ± 13.1	-0.405	0.685
	5th week	29.25 ± 16.77	26.08 ± 13.53	-0.667	0.504

2019
21-23 JUNE
SAN FRANCISCO
SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

The Multinational Association of Supportive Care in Cancer · Annual Meeting 2019 · www.mascc.org/meeting

Nutrition habits of patients

Characteristics	Experimental (n=102)		Control (n=102)			
	n	%	n	%	χ²	р
Nutrition Status						
3 main / 3 main and snacks (Sufficient)	52	51.0	45	44.1	.963	.326
1-2 main and snacks (Insufficient)	50	49.0	57	55.9		
Diet restriction						
Yes	27	26.5	34	33.3	1.146	.284
No	75	73.5	68	66.7		
Fibrous food intake						
Yes	33	32.4	27	26.5	.850	.357
No	69	67.6	75	73.5		
Daily fluid consumption						
2 liters over	35	34.3	37	36.3		
1.5-2 liters	46	45.1	46	45.1	.156	.925
≤1 liters	21	20.6	19	18.6		
Body Mass Index						
Underweight	8	7.8	5	4.9		
Normal (healthy)	48	47.1	46	45.1		
Overweight	25	24.5	31	30.4	2.727	.604
Obese	17	16.7	12	11.8		
Severely obese	4	3.9	2	2.0		

The Multinational Association of Supportive Care in Cancer • Annual Meeting 2019 • www.mascc.org/meeting



SUPPORTIVE CARE MAKES EXCELLENT CANCER CARE POSSIBLE

 $[\]chi^2$: Pearson Chi-Square test; Fisher's Exact Test applied because F: expected number is <1. t: t-test for independent groups, *n=198.

Activity habits of experimental and control group

Activity Status		Experimental Group (n=102)		Control Group (n=102)		χ²	р
			%	n	%		
General	Active	8	7.8	5	4.9		0.39
lifestyle	Sedentary	94	92.2	97	95.1	0.73	
Regularly play	Yes	5	4.9	3	2.9		0.72 ^F
sports / exercise	No	97	95.1	99	97.1		
	Fully active	6	5.9	2	2.0		0.25
	Restricted in physically strenuous activity	8	7.8	11	10.8		
Performance	Up and about more than 50% of waking hours	17	16.7	27	26.5	5.35	
(ECOG)	Confined to bed or chair more than 50% of waking hours	57	55.9	50	49.0	5.55	
	Completely disabled	14	13.7	12	11.8		



The Multinational Association of Supportive Care in Cancer • Annual Meeting 2019 • www.mascc.org/meeting

 χ^2 : Pearson Chi-Square test; Fisher's Exact Test applied because F: expected number is <1. t: t-test for independent groups, *n=198.

Defecation diary stool consistency






1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35.

Experimental ——Control


Defecation diary straining





Experimental ——Control

Defecation diary incomplete evacuation



SUPPORTIVE CARE CANCER CARE POSSIBLE


1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35.




Defecation diary number of defecation








Defecation diary stool amount









VAS scores

Constipation severity




Feeling of fullness in rectum severity






VAS scores

Pain severity



Abdominal gas severity





PACQLQ Scores

| PACQLQ Subscales | | Subscales | | Pre-test | Post-test | | | | |
|------------------|---------------------|-------------------------|--------------|-----------------------------|-------------|--|-------|--|--|
| | | | Groups | ± Sd | ±Sd | t* | р | | |
| The Patier | | at Assessment of | Experimental | 75.69±11.32 | 60.75±10.99 | 21.04 | .0001 | | |
| | | | Control | 71.70±13.55 | 79.01±12.86 | 14.63 | .0001 | | |
| | | on Quality of Life | t** | 2.29 | 14.44 | | | | |
| (| PACQLQ) | | р | .02 | .0001 | | | | |
| | | | Experimental | 11.93±2.21 | 8.99±2.28 | 21.56 | .0001 | | |
| | | Dhusiaal Diagonfort | Control | 10.93±2.33 | 12.34±2.02 | 21.56
10.66
20.52
17.09 | .0001 | | |
| | Physical Discomfort | | 11.12 | | | | | | |
| | | | р | .002 | .0001 | | | | |
| | | Psychosocial Discomfort | Experimental | 21.27±4.99 | 16.00±4.72 | 20.52 | .0001 | | |
| | | | Control | 20.38±4.94 | 24.27±4.59 | 17.09 | .0001 | | |
| | g | | t** | 1.28 | 12.69 | | | | |
| | cale | | р | .20 | .0001 | 5±10.99 21.04 1±12.86 14.63 ±2.28 21.56 1±2.02 10.66 0±4.72 20.52 7±4.59 17.09 7±5.32 18.92 8±6.12 16.68 ±2.90 4.89 | | | |
| | Subscales | | Experimental | 29.69±5.70 | 21.97±5.32 | 18.92 | .0001 | | |
| | Su | Amidaki | Control | 27.49±6.46 | 31.28±6.12 | ±10.99 21.04 ±12.86 14.63 2.28 21.56 ±2.02 10.66 ±4.72 20.52 ±4.59 17.09 ±5.32 18.92 ±6.12 16.68 2.90 4.89 | .0001 | | |
| | | Anxiety | t** | 2.57 | 11.60 | | | | |
| | | | р | 27.49±6.46 31.28±6.12 16.68 | | | | | |
| | | | Experimental | 12.79±3.58 | 9.87±2.90 | 4.89 | .0001 | | |
| | | Catiofaction | Control | 12.89±2.98 | 13.52±2.98 | 1.31 | .19 | | |
| | | Satisfaction | t** | .21 | 8.85 | | | | |
| | | | р | .83 | .0001 | | | | |

<sup>2019
21-23</sup> JUNE
SAN FRANCISCO
SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

Conclusion

In the post-hoc analysis, it was observed that the number of defecations increased by 13%.

2019
21-23 JUNE
SAN FRANCISCO
SUPPORTIVE CARE
MAKES EXCELLENT
CANCER CARE POSSIBLE

The massage application, was observed to improve stool consistency, decrease straining and ease the feeling of incomplete bowel emptying.

Abdominal massage is an effective approach in the management of constipation and can improve the quality of life of patients receiving opioid medication

